Raymond James Initiates Coverage On Polaryx Therapeutics with Strong Buy Rating, Announces Price Target of $6

Benzinga Newsdesk www.benzinga.com Positive 89.9%

Neg 0% Neu 0% Pos 89.9%

Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Strong Buy rating and announces Price Target of $6.